Literature DB >> 8427036

Host range selection of vaccinia recombinants containing insertions of foreign genes into non-coding sequences.

K A Smith1, V Stallard, J M Roos, C Hart, N Cormier, L K Cohen, B E Roberts, L G Payne.   

Abstract

A simple yet powerful selection system was developed for the insertion of foreign genes in vaccinia virus. The selection system utilizes the vaccinia virus K1L (29K) host range gene which is located in HindIII M. This gene is necessary for growth in RK-13 cells but not in BSC40 or CV-1 cells. A vaccinia mutant (vAbT33) unable to grow on RK-13 cells was constructed having sequences at the 3' end of the K1L gene and the adjacent M2L gene deleted and replaced with the beta-galactosidase gene regulated by the BamHI F (F7L) promoter. A recombination plasmid containing the hepatitis B surface (HBs) antigen gene regulated by the M2L promoter and the complete sequence of the K1L gene was used to insert the HBs gene into vAbT33. The M2L negative K1L positive recombinant was easily isolated in two rounds of plaque purification by plating the virus on RK-13 cell monolayers. The K1L gene selection system allows the isolation of recombinants arising at frequencies as low as 1/100,000. It was noted that recombinants containing vaccinia sequence duplications (promoters) resulted in intragenomic recombinations that eliminated all sequences between the duplications. A second recombination plasmid was constructed that allowed insertion into the vaccinia genome without the loss of vaccinia coding sequences. This was achieved by insertion of the pseudorabies virus GIII gene regulated by the vaccinia H5R (40K) promoter between the translation and transcription stop signals at the 3' end of the K1L gene. The K1L gene transcription stop signal thus became the stop signal for the inserted GIII gene and an upstream transcription stop signal present in the H5R promoter fragment provided the stop signal for the K1L gene. This manipulation of the vaccinia genome had no effect on the accumulation or 5' end of the M2L gene transcripts. Although the insertion lengthened the 3' end and lowered the accumulation of K1L transcripts it altered neither the virulence nor the immunogenicity of the recombinant.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8427036     DOI: 10.1016/0264-410x(93)90338-x

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  6 in total

1.  Recombinant vaccinia viruses. Design, generation, and isolation.

Authors:  C C Broder; P L Earl
Journal:  Mol Biotechnol       Date:  1999-12-15       Impact factor: 2.695

2.  Cytotoxic T-lymphocyte cross-reactivity among different human immunodeficiency virus type 1 clades: implications for vaccine development.

Authors:  H Cao; P Kanki; J L Sankalé; A Dieng-Sarr; G P Mazzara; S A Kalams; B Korber; S Mboup; B D Walker
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

3.  Characterization of wild-type and mutant vaccinia virus M2L proteins' abilities to localize to the endoplasmic reticulum and to inhibit NF-kappaB activation during infection.

Authors:  Olivia Hinthong; Xiao-Lu Jin; Joanna L Shisler
Journal:  Virology       Date:  2008-01-10       Impact factor: 3.616

4.  The vaccinia virus A18R DNA helicase is a postreplicative negative transcription elongation factor.

Authors:  Y Xiang; D A Simpson; J Spiegel; A Zhou; R H Silverman; R C Condit
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

5.  Identification of Poxvirus Genome Uncoating and DNA Replication Factors with Mutually Redundant Roles.

Authors:  Baoming Liu; Debasis Panda; Jorge D Mendez-Rios; Sundar Ganesan; Linda S Wyatt; Bernard Moss
Journal:  J Virol       Date:  2018-03-14       Impact factor: 5.103

6.  By Binding CD80 and CD86, the Vaccinia Virus M2 Protein Blocks Their Interactions with both CD28 and CTLA4 and Potentiates CD80 Binding to PD-L1.

Authors:  Patricia Kleinpeter; Christelle Remy-Ziller; Eline Winter; Murielle Gantzer; Virginie Nourtier; Juliette Kempf; Julie Hortelano; Doris Schmitt; Huguette Schultz; Michel Geist; Catherine Brua; Chantal Hoffmann; Yasmin Schlesinger; Dominique Villeval; Christine Thioudellet; Philippe Erbs; Johann Foloppe; Nathalie Silvestre; Laetitia Fend; Eric Quemeneur; Jean-Baptiste Marchand
Journal:  J Virol       Date:  2019-05-15       Impact factor: 5.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.